美国安全用药实践研究所药物不良反应

Hosp Pharm. 2013 Nov;48(10):807-12. doi: 10.1310/hpj4810-807.

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.

此专题的目的是提高对特定药品不良反应（ADR）的认识，讨论预防方法，并促进向美国食品药品监督管理局（FDA）的MedWatch计划（800-FDA-1088）报告药品不良反应。如果您已向MedWatch报告了一起有趣的、可预防的药品不良反应，请考虑与我们的读者分享该案例。写信至ISMP的曼卡诺博士，地址为宾夕法尼亚州霍舍姆市湖滨大道200号200套房，邮编19044（电话：215-707-4936；电子邮件：mmancano@temple.edu）。除非另有要求，您的报告将匿名发表。本专题由安全用药实践研究所（ISMP）与FDA的MedWatch计划以及天普大学药学院合作提供。ISMP是FDA MedWatch的合作伙伴。